Regeneron (REGN)/ Alnylam Report Promising Data from NASH Study

03:29pm, Friday, 16'th Sep 2022 Zacks Investment Research
Regeneron (REGN) and its partner Alnylam announce promising data from its ongoing phase I study evaluating ALN-HSD in healthy adults and NASH patients.
Large companies are set to face a new set of challenges in the coming months stemming from Russia's invasion of Ukraine, rising interest rates, and the COVID-19 pandemic.

Where Alnylam Pharmaceuticals Stands With Analysts

04:24pm, Friday, 09'th Sep 2022 Benzinga
Within the last quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 1 8 0

Analyst Ratings for Alnylam Pharmaceuticals

01:33pm, Friday, 09'th Sep 2022 Benzinga
Analysts have provided the following ratings for Alnylam Pharmaceuticals (NASDAQ:ALNY) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 1

Alnylam (ALNY) Soars 8.4%: Is Further Upside Left in the Stock?

12:39pm, Friday, 09'th Sep 2022 Zacks Investment Research
Alnylam (ALNY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the roa
Alnylam (ALNY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the roa

Want to Beat Alphabet Stock? Buy These 2 Winners of the Bear Market

02:45pm, Sunday, 04'th Sep 2022 The Motley Fool
They're both soaring thanks to a handful of recent catalysts.
They're both soaring thanks to a handful of recent catalysts.

Emergent Biosolutions (EBS) Down 20% Since Last Earnings Report: Can It Rebound?

03:30pm, Wednesday, 31'st Aug 2022 Zacks Investment Research
Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Biotech stocks are scorching right now. But the best of the best have strong gains.

Alnylam (ALNY) Up More Than 60% in Past 3 Months: Here's Why

05:35pm, Friday, 26'th Aug 2022 Zacks Investment Research
Alnylam's (ALNY) portfolio of approved drugs is witnessing a strong uptake while its pipeline is progressing well. The recent FDA approval of Amvuttra for a rare disease is a positive.
Alnylam's (ALNY) portfolio of approved drugs is witnessing a strong uptake while its pipeline is progressing well. The recent FDA approval of Amvuttra for a rare disease is a positive.
Alnylam is rapidly becoming the leader in ATTR through its successful therapy, patisiran. Intellia has presented data showing even deeper reductions in TTR.
Alnylam Pharmaceuticals stock (NASDAQ: ALNY), a pharmaceutical company focused on RNA interference therapeutics for genetically defined diseases, has seen a significant rise of 51% in a month.

3 Biopharmas on Buyout Watch

12:00pm, Monday, 22'nd Aug 2022 The Motley Fool
These three biotech companies could be headed for a buyout soon.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE